GRTX insider filings
Galera Therapeutics, Inc. — 37 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-08-05. Screen GRTX transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 6 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 15.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| CHANG NANCY T — Director, 10% owner | 1 | — | — | 4 |
| FRIEDMAN MICHAEL R. — Director | 1 | — | — | 4 |
| Alleva Lawrence M — Director | 1 | — | — | 3 |
| Sorensen Mel — President and CEO, Director | 1 | — | — | 2 |
| LOKAY KEVIN G — Director | 1 | — | — | 1 |
| Sussman Joel F. — Chief Accounting Officer | 1 | — | — | 1 |
Recent insider filings — Galera Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-05 | 4 | Sorensen Mel — President and CEO, Director | Disposition to issuer (D): 975 · Disposition to issuer (D): 30,000 (derivative) | EDGAR |
| 2026-08-05 | 4 | Alleva Lawrence M — Director | Disposition to issuer (D): 11 · Disposition to issuer (D): 40 · Disposition to issuer (D): 240 (derivative) | EDGAR |
| 2026-08-05 | 4 | CHANG NANCY T — Director, 10% owner | Conversion (C): 661,309 · Disposition to issuer (D): 47,434 · Conversion (C): 661.31 (derivative) @ $0 · Disposition to issuer (D): 480 (derivative) | EDGAR |
| 2026-08-05 | 4 | LOKAY KEVIN G — Director | Disposition to issuer (D): 240 (derivative) | EDGAR |
| 2026-08-05 | 4 | FRIEDMAN MICHAEL R. — Director | Conversion (C): 2,989,399 · Disposition to issuer (D): 41,631 · Conversion (C): 2,989.40 (derivative) @ $0 · Disposition to issuer (D): 480 (derivative) | EDGAR |
| 2026-08-05 | 4 | Sussman Joel F. — Chief Accounting Officer | Disposition to issuer (D): 10,000 (derivative) | EDGAR |
| 2026-05-29 | 4 | Emerald Bioventures, LLC — 10% owner Opler Timothy — 10% owner | Conversion (C): 20,813,818 · Conversion (C): 20,813.82 (derivative) | EDGAR |
| 2026-04-09 | 4 | FRIEDMAN MICHAEL R. — Director | Conversion (C): 5,336,870 · Conversion (C): 5,336.87 (derivative) @ $0 | EDGAR |
| 2026-04-09 | 4 | CHANG NANCY T — Director, 10% owner | Conversion (C): 1,180,611 · Conversion (C): 1,180.61 (derivative) @ $0 | EDGAR |
| 2025-11-24 | 4 | Sorensen Mel — President and CEO, Director | Sale (S): 70,000 @ $0.02 | EDGAR |
| 2025-05-05 | 4 | Sussman Joel F. — Chief Accounting Officer | Grant/award (A): 2,000,000 (derivative) @ $0 | EDGAR |
| 2025-05-05 | 4 | Sorensen Mel — President and CEO, Director | Grant/award (A): 6,000,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | FRIEDMAN MICHAEL R. — Director | Grant/award (A): 96,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Alleva Lawrence M — Director | Grant/award (A): 48,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | LOKAY KEVIN G — Director | Grant/award (A): 48,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | CHANG NANCY T — Director, 10% owner | Grant/award (A): 96,000 (derivative) @ $0 | EDGAR |
| 2025-01-02 | 4 | FRIEDMAN MICHAEL R. — Director | Grant/award (A): 8,326.27 (derivative) @ $0 | EDGAR |
| 2025-01-02 | 4 | CHANG NANCY T — Director, 10% owner | Purchase (P): 7,644,932 @ $0.07 · Grant/award (A): 1,841.92 (derivative) @ $0 | EDGAR |
| 2024-08-20 | 4 | Sorensen Mel — President and CEO, Director | Sale (S): 67,015 @ $0.07 | EDGAR |
| 2024-05-01 | 4/A | Schneid Yair — 10% owner | Purchase (P): 318,150 @ $0.19 · Purchase (P): 100,000 @ $0.19 · Purchase (P): 68,424 @ $0.20 · Purchase (P): 241,028 @ $0.20 · Purchase (P): 56,900 @ $0.21 · Purchase (P): 50,000 @ $0.21 · +15 more | EDGAR |
| 2024-02-26 | 4 | Schneid Yair — 10% owner | Purchase (P): 150,000 @ $0.18 · Purchase (P): 335,000 @ $0.18 · Purchase (P): 97,402 @ $0.18 · Purchase (P): 25,000 @ $0.20 · Purchase (P): 25,000 @ $0.17 · Purchase (P): 150,000 @ $0.17 · +1 more | EDGAR |
| 2023-07-05 | 4 | West Linda — Director | Grant/award (A): 23,382 (derivative) @ $0 | EDGAR |
| 2023-07-05 | 4 | Alleva Lawrence M — Director | Grant/award (A): 22,762 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | West Linda — Director | Grant/award (A): 48,000 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | Cunningham Emmett — Director | Grant/award (A): 48,000 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | Alleva Lawrence M — Director | Grant/award (A): 48,000 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | LOKAY KEVIN G — Director | Grant/award (A): 48,000 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | POWELL MICHAEL — Director | Grant/award (A): 64,000 (derivative) @ $0 | EDGAR |
| 2023-03-20 | 4 | Bachleda Mark — Chief Commercial Officer | Purchase (P): 11,000 @ $2.25 | EDGAR |
| 2023-03-14 | 4 | Degnan Chris — Chief Financial Officer | Purchase (P): 10,000 @ $1.96 | EDGAR |
| 2023-03-14 | 4 | Sorensen Mel — President and CEO, Director | Purchase (P): 100,000 @ $1.68 | EDGAR |
| 2023-02-28 | 4 | Degnan Chris — Chief Financial Officer | Grant/award (A): 185,000 (derivative) @ $0 | EDGAR |
| 2023-02-28 | 4 | Kennedy Eugene P. — Chief Medical Officer | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2023-02-28 | 4 | Bachleda Mark — Chief Commercial Officer | Grant/award (A): 135,000 (derivative) @ $0 | EDGAR |
| 2023-02-28 | 4 | Sorensen Mel — President and CEO, Director | Grant/award (A): 440,000 (derivative) @ $0 | EDGAR |
| 2023-02-28 | 4 | Stacey Jennifer Evans — See Remarks | Grant/award (A): 135,000 (derivative) @ $0 | EDGAR |
| 2023-02-28 | 4 | Beardsley Robert A — Chief Operating Officer | Grant/award (A): 135,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Galera Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-31 | 8-K | 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-13 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-07 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-05-19 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-05-15 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-04-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.01 — Changes in Control of Registrant 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-09 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-04-03 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=GRTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →